Bicara Therapeutics (BCAX) Non-Current Assets (2023 - 2026)

Bicara Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 18.59% year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was $154.1 million, a 657.28% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, up 19.8% from the prior year.
• Non-Current Assets slipped to $8.7 million in Q1 2026 per BCAX's latest filing, from $8.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $127.3 million in Q3 2025 and bottomed at $2.7 million in Q3 2024.
• The 4-year median for Non-Current Assets is $8.1 million (2024), against an average of $21.8 million.
• Across the five-year window, Non-Current Assets jumped 4688.12% in 2025 and advanced 18.59% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $2.9 million in 2023, then soared by 156.55% to $7.5 million in 2024, then grew by 19.8% to $8.9 million in 2025, then declined by 2.87% to $8.7 million in 2026.
• Per Business Quant, the three latest BCAX Non-Current Assets figures stand at $8.7 million (Q1 2026), $8.9 million (Q4 2025), and $127.3 million (Q3 2025).